BD Moves The Needle To High Growth Segments

Exploiting The Trend To Pharmacy Automation And Remote Patient Care

Becton Dickinson is investing in high-growth segments and is on a mission to simplify its business. CEO Tom Polen’s 2025 strategy targets 25% operating margin from both innovations and durable core business combined, as senior BD executives told In Vivo during a break at J.P. Morgan 2024.

Added Value
• Source: Shutterstock

Becton, Dickinson and Company (BD) is in a transformative period in its development. The medication delivery to lab tests and biosciences research company has been reinventing itself and its approach to the evolving medtech market in the past decade. The die was cast when the now 127-year-old company bought CareFusion Corporation in 2015 and then in 2017 followed it with another major transaction, the purchase of C.R. Bard.

Those acquisitions helped BD to almost triple its revenues in the following years. Then in 2020, chair, CEO and president...

More from Leadership

More from Medtech Insight

Commission Decision Launches Pediatric And Rare Disease Expert Group

 

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.

US CMS Sets Out Competitive Bidding Rental Model for CGMs; Abbott, Dexcom Could Face Impact

 
• By 

CMS is proposing to classify all CGMs and insulin pumps as “items requiring frequent and substantial servicing” to expand device choice and access for Medicare beneficiaries. Under this framework, CMS also intends to move Class II devices, which include CGMs from Abbott and Dexcom and pumps from Tan

Dermal Fillers For Décolletage May Gain FDA Approval

 
• By 

An upcoming US FDA advisory panel meeting will discuss adding a new indication to allow dermal fillers to be used in the upper chest, or décolletage. Plastic surgeons expect this could drive interest in the procedure, which is already performed off-label.